Head-to-head K drug Hengrui enters the game

Recently, Hengrui Medicine registered both carrelizumab + famitinib head-to-head pembrolizumab in CDE and ClinicalTrials.

From: Insight database (http://db.

According to incomplete statistics from Insight, this is the largest K-drug head-to-head clinical trial initiated by domestic PD-1/L1, recruiting 706 patients worldwide, of which China plans to enroll 500 cases

Domestic PD-1/L1: Active head-to-head research

Recently, the head-to-head research of domestically produced PD-1/L1 has been active.

PD-1/L1 head-to-head K drug clinical trial

In the wave of domestically produced PD-1, the comparison of the efficacy with K drugs may be a problem that companies need to face, because K drugs are now the standard first-line treatment of NSCLC in the United States

However, single-agent head-to-head K drugs are unlikely to succeed.

From the perspective of the combination plan, Baiji is an immune combination therapy, PD-1 monoclonal antibody combined with TIGIT monoclonal antibody, Roche has previously verified the efficacy of this combination with amazing clinical data; Tianqing and Hengrui both use PD-1 /L1 combined with a small molecule multi-target tyrosine kinase inhibitor

Carrelizumab combined with famitinib: 1+1>2

The results of a number of studies have confirmed that anti-PD-1/PD-L1 antibodies combined with anti-angiogenesis targeted drugs can produce synergistic effects

Famitinib Malate Capsules is a small molecule multi-target tyrosine kinase inhibitor independently developed by Hengrui Medicine.

Clinical registration of carrelizumab + famitinib combination therapy

(From Insight database)

Among them, the indications for cervical cancer have progressed the fastest, and phase III clinical trials have been launched in June 2021

From: CDE official website

Overseas, Carrelizumab has also made a number of clinical advances

From: Hengrui Semi-annual Report